PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Research on Novel Liposomes

Company: Silo Pharma Inc. (SILO)
Category: Stock Spotlights

Silo Pharma (OTCQB: SILO) recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”). “Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, SPU-21 can potentially be used to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. According to the research, this approach may enhance therapeutic effects and decrease potential toxicity despite systemic administration of the drug,” a recent article reads. “In addition, Silo recently announced positive results in subcutaneous delivery of its novel liposomes to treat arthritic patients. This contrasts with previous animal research testing ART-1-Cy7 liposomes using intravenous injection, suggesting that subcutaneous administration possibly trends higher than intravenous injection with fewer toxic effects. ‘The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents,’ said Silo Pharma CEO Eric Weisblum. ‘We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity.’”

To view the full article, visit https://ibn.fm/rAbFk

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050